C4 Therapeutics Inc Stock, NASDAQ:CCCC
490 Arsenal Way, Suite 200, Watertown, Massachusetts 02472
United States of America
Number of Employees: 99
C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.